Headline: Dengue Vaccination Landscape: Challenges and Hopes in [Country Name]
In the ongoing battle against dengue, a viral infection spread by mosquitoes, the world is eagerly awaiting the expansion of vaccination options. Currently, two vaccines are authorized for use, but both face significant hurdles in widespread application.
Dengvaxia and Qdenga: The Current Landscape
Sanofi Pasteur’s Dengvaxia, the first dengue vaccine to reach the market, is approved for individuals aged 9 to 45 who have previously had dengue. However, its use has been limited due to low demand and specific administration requirements. Meanwhile, Takeda’s Qdenga, approved for use in children aged 4 and above, faces supply constraints due to high global demand and production limitations.
Dr. Cousirat, a spokesperson for the Ministry of Public Health and Social Security (MSPBS), expressed optimism about Qdenga’s production improvement and anticipation for a third vaccine under development by Brazil’s Instituto Butantan. This vaccine, currently in the registration phase, promises to be more accessible and locally produced in significant quantities.
Accessibility and Cost
The MSPBS has formally requested doses of Qdenga, but limited availability has made access challenging, with other countries like Brazil and Argentina also vying for supplies. While the cost is yet to be determined, preliminary estimates by the Pan American Health Organization (PAHO) suggest a price of US$ 19.20 per dose.
Once available, the vaccines will be integrated into the national immunization calendar, prioritizing children aged 5 to 14, who are most vulnerable to severe dengue cases. With over 1,400 vaccination centers ready, the country is well-positioned to distribute the vaccine effectively, mirroring successful models used for other diseases like yellow fever.
Beyond Vaccination: A Holistic Approach
While welcoming vaccination as a critical tool, Dr. Cousirat emphasized the importance of eliminating mosquito breeding grounds. The Aedes Aegypti mosquito, responsible for dengue transmission, also spreads other diseases like chikungunya, yellow fever, and zika.
Current Trends and Future Prospects
Despite a decrease in dengue and chikungunya cases so far in 2025, Dr. Cousirat warned against complacency, citing favorable conditions for mosquito breeding due to persistent rains and high temperatures. Although vaccines for other vector-borne diseases are in development, production limitations and high demand pose significant challenges.
As the country awaits the expansion of vaccination options, it continues to prioritize prevention and community education as essential weapons in the fight against these endemic diseases. Collaboration with neighboring countries like Brazil and Argentina is crucial to strengthen regional health security.
Stay tuned for updates on dengue vaccination developments and health news in [Country Name].
Sources: Ministry of Public Health and Social Security, Pan American Health Organization
Worth a look